US Tariffs Threaten Indian Pharma Exports

Indian pharmaceutical stocks experienced a significant downturn on Wednesday subsequent to US President Donald Trump's tariff announcement. Proposed tariffs, set to take effect from August 2028, would impose a 100% levy on imported generic drugs, escalating further the following year. This development is particularly concerning for companies with substantial revenue derived from the US market.

Analysts recommend that investors now prioritize pharmaceutical firms with a stronger domestic focus. The Nifty Pharma index recorded a 1.3% decrease by market close, with the benchmark Nifty 50 also falling by 0.8%. Several major Indian drug manufacturers, including Lupin, Piramal Pharma, and Ajanta Pharma, saw notable declines in their stock values.

Despite the immediate market reaction, some experts believe the impact may not be severe in the short term. They point out that the proposal is in its early stages and anticipate further negotiations. India's position as a key supplier of affordable generic medicines to the US is a significant factor that could influence these discussions. The pharma sector has recently outperformed the broader market, with the Nifty Pharma index showing a 13.3% gain year-to-date in 2026, contrasting with the Nifty 50's decline of 8.2%.